A similar bill appeared last year but did not progress. Given the potential costs of reimbursing prescription digital therapeutics, Congress could be skeptical. Still, with growing attention on mental health, advocates are optimistic.

Conducted by researchers at the University of Colorado medical school, the new report is the latest to gauge the extent of a costly problem that federal regulators are working to solve: Information about doctors varies from provider directory to provider directory.

Hospitals, clinics, nursing homes and other providers collected billions in government aid during the pandemic. Federal auditors may soon come knocking to ensure the money was spent correctly.

Disgruntled investors lodged fewer securities claims against life-science companies last year. But when they did sue, investors raised familiar issues, often tied to bad news around clinical research and regulatory approvals, according to a law firm report

High prices have drawn other critics, as well, including President Joe Biden. He renewed his call for a broad price cap during his annual State of the Union address. Pharma companies insist they have been part of the solution.

The innovation platform promises to match entrepreneurs with the resources they need to advance treatments for stroke care but also to help the device maker process all the new ideas it sees.

The industry faces challenges from inflation to labor shortages, according to an annual report from EY. However, there are grounds for optimism and areas to focus on, such as patching up supply chains.

President of Humana’s primary care, Reneé Buckingham, addresses the needs of many seniors facing multiple diagnoses and barriers to high-quality care.

Based in San Francisco, Allermi aims to create a national market for a customizable approach to allergy relief pioneered by a California doctor.

Alira Health hopes its purchase of RedCrow will help it stand out from the crowd of consulting firms that help life sciences companies bring drugs to market.

Moximed snagged $40 million as it works to secure approval for its device, an implantable shock absorber for the knee designed to put off the need for full joint replacement. CEO Anton Clifford touts that the MISHA Knee System is the first of its kind.

Decentralized clinical trial approaches helped the pharma industry navigate through Covid-19. Now it is becoming increasingly clear that there’s a need for a hybrid approach to decentralized clinical trials that considers the perspectives of patients and the impact to clinical trial sites.

Rising deal premiums and shrinking profit margins are threatening the sustainability of the traditional approach to mergers and acqusitions, according to a report by Accenture. The firm expects growth-minded companies will turn to other pathways.

The company is making its online staffing platform available to people seeking jobs as physical therapists, surgical techs and other allied health professions.

A veteran of GE Healthcare, Joe Gasque talks about how he's growing the company's niche position in the high-paced aesthetics industry, offering services to surgeons, practitioners, medical device and injectables manufacturers.

The nonprofit Digital Medicine Society is partnering with the likes of Google and the FDA to develop a free resource designed to help digital health startups navigate the regulatory process.

The peer-reviewed research is among the first to examine the effectiveness of the new crop of digital mental health startups. It looked at people enrolled through their companies in a mental health platform developed by Spring Health.

During first three months of 2022, biopharma tech companies raised less money and made fewer deals than they did in the last three months of 2021. A volatile stock market is exacerbating the trend.

Armed with fresh capital, Nava Benefits hopes to take advantage of what it believes will be a disruption in the way smaller businesses approach health and wellness benefits, including the many digital tools now on the market.

Pharma companies often take the blame for high prescription costs. But a new, industry-sponsored survey shifts attention to insurance industry practices.

UK-based OMass Therapeutics is leaning on a proprietary form of native mass spectrometry to help develop small-molecule drugs for rare diseases.

The tests could prove useful in screening patients that coud benefit from therapies being tested for Alzheimer’s. But uptake will depend, in part, on reimbursement, according to doctors surveyed by Quest.

San Francisco-based Frame Fertility has developed a platform geared toward helping people get a headstart on issues that could impact their ability to have children instead of waiting until problems crop up.

Executives used to lean toward European regulators launching their products in that region. But after a decade of change, they now see the U.S. as a better option. While the FDA gets kudos, the other issue remains challenging: reimbursement.

The partners aim to make decentralized clinical trials more efficient and less expensive through greater use of AI and machine learning.

Brokerage firm Nava Benefits hopes its search engine will become a trusted source of information on thousands of digital health startups aiming to sell their services to employers.

Prenosis is aiming for FDA clearance this year for a diagnostic tool for sepsis, a condition that kills millions of people each year.

Lawmakers have acted to strengthen insurance reimbursement for biomarker testing in California, Illinois and Louisiana. Patient advocates and testing companies hope more will act in the coming year.

Researchers have known for decades that viruses can beat back cancer. But it’s been hard to design a virus that does the trick. A new wave of startups is optimistic they have found the keys.